Workflow
Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues
APLSApellis(APLS) Zacks Investment Research·2024-01-09 16:16

Apellis Pharmaceuticals (APLS) reported net product sales of approximately 138millionintheUnitedStatesforthefourthquarterof2023,upsignificantlyyearoveryear.Thecompanygeneratesproductrevenuesfromthesaleofitstwomarketeddrugs,Empaveli(pegcetacoplan)andSyfovre(pegcetacoplaninjection).Itstoplinealsocomprisesoflicensingandotherrevenues.The39138 million in the United States for the fourth quarter of 2023, up significantly year over year. The company generates product revenues from the sale of its two marketed drugs, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection). Its top line also comprises of licensing and other revenues.The 39% sequential increase in product revenues (from 99.2 million) was driven by strong Syfovre sales. Syfovre recorded sales of $11 ...